Tags Posts tagged with "GWPH"

GWPH

0 2523

The biotech sector will be one of the greatest beneficiaries of the global cannabis movement and is comprised of some of the most mature and best capitalized companies.

The Nasdaq was the worst performing exchange yesterday and biotech cannabis-focused firms traded lower on average. Although we continue to be bullish on this sub-sector of the cannabis industry, it is also the one that would be most impacted by a correction in the market.

This sector is comprised of some of most attractive long-term companies. We think recent weakness has created opportunity and we want to highlight five cannabis stocks every investor should be watching.

Insys Therapeutics (INSY) traded in a very volatile range after reporting its fourth quarter and full year financial results yesterday. Insys opened down almost 5% and the shares traded as low as $10.01 before finding support. INSY bounced off these lows and the shares ended the day up 2.2%. INSY is at $10.75 and Technical420 plans to average down and add to its position if the shares trade below $10. The shares are trading well below its average Wall Street price target (more than 60% upside to average price target). One of the main reasons why we are favorable on Insys is because we view the company as an acquisition candidate due to its valuable intellectual property and relatively cheap valuation.
Corbus Pharmaceuticals (CRBP) gave up all its gains from Monday and the shares are trading at $8.05 after a 2.4% move lower on weak volume. We continue to monitor CRBP from the sidelines after exiting our position within hours of entering. We are on the sidelines due to the misleading reports, the increased volatility, and the potential for the market to dip lower in the near term.
Cara Therapeutics (CARA) was under pressure yesterday and the shares are trading below the pricing of its recently announced financing. Technical420 remains favorable on Cara Therapeutics and see significant upside to current levels. The shares are trading at $17.92 after a 2.5% move lower and we plan to add to our position on continued weakness. Cara plans to use the proceeds from its $80 million raise to fund clinical and R&D activities, including the completion of the Phase 3 program in uremic pruritus, two Phase 3 trials in acute pain and a Phase 2b trial in osteoarthritis pain. We will keep you updated on how the shares trade today.
GW Pharmaceutical (GWPH) edged lower on light volume yesterday and the shares are currently trading below its 20 and 50-day moving average. GWPH has fallen 8% in the last month and we view the shares as an attractive long-term opportunity at current levels. GW has one of the deepest pipelines of products in advanced stages of FDA testing. The company also has the best Wall Street coverage and has received buy ratings from Goldman Sachs, Merrill Lynch, and Morgan Stanley. We view GW as an acquisition candidate and Goldman Sachs estimated a $390 a share acquisition price if that was to occur. From the filing of a New Drug Application to multiple Phase 3 Clinical trials, GW Pharma is an event-driven story that has many potential catalysts. We plan to hold and add to our position on continued weakness.
Zynerba Pharmaceuticals (ZYNE) continues to be one of the most attractive cannabis biotech investment opportunities due to the relatively cheap valuation, its high-quality pipeline of products, the number of upcoming catalysts, and its favorable and improving Wall Street coverage. In late March, H.C. Wainwright raised Zynerba’s price target to $30 from $22. The average price target on shares of Zynerba is north of $30 and offers more than 50% upside to current levels.

1 5185

Cannabis stocks have come down from their recent highs and this has raised some concerns after we ended 2016 on a high note.

2016 was a great year for the cannabis industry and we expect 2017 to build off this success. From Canada to Australia, the United States to Germany, the global cannabis industry continued to expand and the stage is set for growth for years to come.

The recent weakness has led to an influx of questions pertaining to the top cannabis investment opportunities and we want to highlight 7 cannabis stocks that investors should watch during 2017.

Seven Cannabis Stocks to Watch

1. GW Pharmaceuticals (GWPH): We continue to view GWPH as the top long-term biotech investment levered to the cannabis industry and we expect to see a VERY STRONG second half of the year. We are favorable on the long-term outlook due to its deep pipeline of products in advanced stages of clinical trials, its strong balance sheet, and its favorable Wall Street coverage.

2. Zynerba Pharma (ZYNE): We consider the company to be one of the most undervalued biotech investment opportunities. Zynerba is focused on developing treatments from synthetic cannabis and the average Wall Street price target offers almost 100% upside to current levels.

3. Canopy Growth (WEED.TO) (TWMJF) continues to be the leader in the Canadian medical cannabis industry and view the company as one the best opportunities within the cannabis industry. The shares have been trending lower and we view this weakness as a great opportunity to buy into a high-quality cannabis producer with a global footprint.

4. Emblem Corp. (EMC.V) (EMMBF) has been trending so far this year and the shares are down 30% during this time. Despite the recent weakness, we are bullish on the company’s opportunity due to its attractive business model, its proven management team, its sound financial structure, its strong balance sheet, and its leverage to growth trends in the cannabis sector

5. After securing a potentially highly lucrative licensing contract, InMed Pharmaceuticals, (IN.CN) (IMLFF) looks even better positioned to benefit for positive tailwinds facing the global cannabis industry. InMed is a pre-clinical biopharmaceutical company that is focused on the research and development of novel and cannabinoid-based therapies in Canada. The company has a strong pipeline of products in various stages of FDA testing and is developing various drugs for diseases, such as ocular, pain and inflammation.

6. VPR Brands, LP, (VPRB) is a stock to watch as it is levered to several growth trends within the global cannabis industry. The shares have pulled back and we see upside to current levels. In 2016, VPR acquired Vapor Corp’s wholesale operations and assets for a significant discount and recent announcements show that VPR has executed on and monetized this acquisition. We view this as a very attractive growth story that is undervalued by the street.

7. Vinergy (VIN.CN) (VNNYF) has been one of the most interesting and exciting stories to watch over the last six months and we see significant upside to current levels. The shares have fallen more than 33% in the last month and we find them to be attractive due to the number of catalysts for growth over the next year.

Disclaimer:
Pursuant to an agreement between MAPH and InMedPharmaceuticals., we were hired for a period beginning February 24 2017 and ending April 24, 2017 to publicly disseminate information about (IMLFF) including on the Website and other media including Facebook and Twitter. We are being paid $40,000 (CASH) for and were paid “250,000” shares of restricted common shares of InMed Pharmaceuticals.Pursuant to an agreement between MAPH and VPRBrands, we were hired for a period of 90 days to publicly disseminate information about (VPRB) including on the Website and other media including Facebook and Twitter. We are being paid $45,000 (CASH) for or were paid “ZERO” shares of unrestricted or restricted common shares. We own zero shares of (VPRB) which we purchased in the open market. Pursuant to an agreement between MAPH and Vinergy Resources, we were hired for a period of 2 months to publicly disseminate information about (VNNYF) including on the Website and other media including Facebook and Twitter. We are being paid $120,000 (CASH) for or “ZERO” shares of restricted or unrestricted common shares. We own zero shares of (VNNYF) which we purchased in the open market. We may buy or sell additional shares of (IMLFF, VPRB, VNNYF) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.

0 3127

Countries across the globe continue to legalize cannabis and it is only a matter of time until the U.S. gets on the bandwagon.

The biotech sector will be one of the greatest beneficiaries of legal cannabis and companies focused on this opportunity have outperformed the market over the last quarter.

A Stock to Watch

Today, Vinergy Resources (VIN: CSE) (VNNYF: OTCQB) reported a breakthrough while conducting R&D on its oral cannabinoid (CBD) delivery strips and controlled time release capsule technology.

We highlighted VIN.CN as a stock to watch after its acquisition of MJ Biopharma in mid-December and the market responded very favorably to this all-stock purchase. MJ Biopharma is a private cannabis technology company focused on manufacturing breath strips, time release capsules, extract oils, food products such as infused juices, teas, coffee and extract drinks, as well as the development of pharmaceutical grade delivery systems.

MJ Biopharma is also focused on licensing and partnering on the development of technologies and products for the medical and recreational cannabis market in Canada and abroad. The company said that the novel approach that is under development will become the basis for new products where water or saliva is the catalyst used to activate the carrier for delivery and absorption of CBD in the body.

Opportunity to Create a New Product Category

This unique approach forms the basis for a fundamentally new technology and possible new product category. The technology is called BURST due to the speed at which it can enhance the body’s absorption of various ingredients. The BURST system is built on natural botanical polymers delivering specialty processed high purity cannabinoids.

MJBiopharma CEO Kent Deuters said, “This is a great breakthrough for us and the product line we have planned. The technology can also be utilized in our time release capsules which of course will have a slower absorption rate. We think time release capsules are extremely important as they help bridge the gap in terms of familiarity with many patients who want to switch from synthetic drugs to a natural drug as a way to reduce side effects, reduce drug costs and just feel better all around.”

Two Top Picks

Two other biotech cannabis stocks we are watching are Zynerba Pharmaceuticals (ZYNE) and GW Pharmaceuticals (GWPH).

GWPH has rallied off its recent lows and we remain bullish on the company due to its deep pipeline of pharmaceutical products that are in advanced stages of FDA testing. The company has several catalysts in the back half of 2017 and we see significant upside to current levels.

ZYNE continues to remain one of our top picks in the cannabis sector as we see significant upside to current levels. The average Wall Street price target on ZYNE is north of $30 and we view the company as an acquisition candidate for any biotech company interested in the cannabis industry.

We continue to view GWPH as one of the top investment opportunities within the cannabis sector as it is the only Nasdaq traded company focused on developing treatments from the actual cannabis plant.

Unlike Zynerba Pharmaceuticals (ZYNE) which develop its treatments from synthetic cannabis, GWPH uses the actual cannabis plant and the benefits of this are reflected in its continued success in FDA trials.

0 1127

Cannabis biotech bellwether, GW Pharmaceuticals (GWPH) announced positive top-line results from an exploratory Phase 2 placebo-controlled clinical study of a proprietary combination of tetrahydrocannabinol (THC) and cannabidiol (CBD) in 21 patients with recurrent glioblastoma multiforme (GBM).

Concurrent with this announcement, the company also reported first quarter financial results for the period that ended on December 31st. GW Pharma continues to be a leader within the cannabis biotech sector and today’s announcement further solidify its position at the top.

About the Study

GBM is a particularly aggressive brain tumor, with a poor prognosis. GW Pharma was granted the Orphan Drug Designation from the FDA and the EMA for THC:CBD in the treatment of glioma.

The study showed that patients with documented recurrent GBM treated with THC:CBD had an 83% one-year survival rate compared with 53% for patients taking the placebo. The median survival for the THC:CBD group was greater than 550 days compared with 369 days in the placebo group.

The treatment was generally well tolerated with the patients in both groups. The study reported that emergent adverse events caused two patients in each group to discontinue the study. The most common adverse events reported were vomiting and dizziness.

From the Principal Investigator and the CEO

Professor Susan Short, PhD, Professor of Clinical Oncology and Neuro-Oncology at Leeds Institute of Cancer and Pathology at St James’s University Hospital and principal investigator of the study said, “The findings from this well-designed controlled study suggest that the addition of a combination of THC and CBD to patients on dose-intensive temozolomide produced relevant improvements in survival compared with placebo and this is a good signal of potential efficacy. Moreover, the cannabinoid medicine was generally well tolerated. These promising results are of particular interest as the pharmacology of the THC:CBD product appears to be distinct from existing oncology medications and may offer a unique and possibly synergistic option for future glioma treatment.”

2017 Outlook is Bright

Following the company’s earnings report, GW Pharma CEO Justin Gover said, “As we look forward to 2017, our primary focus is on completing the Epidiolex NDA, which we expect to submit to the FDA in the middle of this year. With three positive Phase 3 trials delivered in 2016, we remain confident in the prospects for Epidiolex’s approval and are accelerating our preparations for a highly successful launch. Beyond Epidiolex, the value of GW’s cannabinoid platform is further illustrated by promising new clinical data in the field of oncology and we continue to advance a number of additional clinical programs that will yield data this year.”

Trades on FDA Results, Not Earnings

Although GW Pharma reported a $19.3 million net loss on $2.5 million in revenue during the quarter, we remain very favorable on the company as biotech stocks tend to trade on FDA results, not earnings.

As of December 31st, the company reported to have $444.6 million in cash and cash equivalents. This should provide the company enough capital to execute on 2017 corporate initiatives.

We are favorable on this update and continue to view GWPH as one of the top investment opportunities for cannabis investors due to its deep pipeline of products that are in advanced stages of FDA testing. The company’s pipeline should create catalysts for years to come and this is a stock every investor should watch.

0 2284
cannabis biotech

Federal authorities charged another doctor with health-care fraud after receiving kickback from Insys Therapeutics (INSY) in return for prescribing one of its highly addictive opioid products. In mid-2015, we reported on this story and urged caution with shares of INSY due to our expectation for future legal headwinds. Our prediction proved to be accurate and INSY has fallen by more than 75% since we published this article.

Although we continue to forecast increased volatility with INSY in the near-term, we expect to see the company acquired by a larger biotech firm interested in the cannabis industry this year and see significant upside to current levels. The Pay for prescriptions fallout has created an opportunity for retail investors familiar with INSY and their drug therapies, namely Syndros which got FDA clearance in July of 2016.

Biotech Bets Continue to Pay Off

The biotech sector will be one of the greatest beneficiaries of legal cannabis and companies focused on this opportunity have outperformed the market over the last quarter.

We highlighted Vinergy Resources (VIN.CN) (VNNYF) as a stock to watch after its acquisition of MJ Biopharma in mid-December and the market responded very favorably to this all-stock purchase.

Yesterday, Vinergy announced that it signed a letter of intent to acquire up to 51% of a European multi-national plant breeding company that has $14+ million in annual sales and adjusted EBITDA $2+ million.

Becoming a Global Cannabis Opportunity

The target acquisition has been providing customers with commercial agriculture services for more than 25 years. During 2016, the company shipped 35+ million plant products to its customers and it continues to see incremental growth opportunities.

Through Vinergy, the company will be able to expand into the European cannabis industry. As part of the acquisition, Vinergy will now have access to 2,000+ hemp and cannabis strains with the ability to supply those strains to global customers.

The terms and conditions associated with the transaction were not disclosed but management expects the transaction to close in tranches with the first being it the first quarter of 2017.

A Stock to Watch

We continue to be bullish on Cara Therapeutics, Zynerba (ZYNE) and GWPH as possible acquisition targets by Pharma companies as Jason Spatafora (@Wolfofweedst) stated in a July 26th piece for Forbes. We will keep you updated on progress in this sector as usual…

0 1684

From the National Cancer Institute (NCI) to the National Institute on Drug Abuse (NIDA), U.S. government agencies continue to change its stance pertaining to medical cannabis.

Last year, the NCI updated its website to include various studies that reveal how cannabis may inhibit tumor growth by killing cells. The NIDA revised their April 2015 publication to say that marijuana can kill certain cancer cells and reduce the size of others.

Countries across the globe continue to legalize cannabis and it is only a matter of time until the U.S. gets on the bandwagon. Although the market continues to keep its eyes on the U.S. cannabis industry, its neighbors to the north continue to be the global cannabis leader.

Biotech Bets

The biotech sector will be one of the greatest beneficiaries of legal cannabis and companies focused on this opportunity have outperformed the market over the last quarter.

We highlighted Vinergy Resources (VIN.CN) as a stock to watch after its acquisition of MJ Biopharma in mid-December and the market responded very favorably to this all-stock purchase.  At the time of this announcement, Vinergy also announced a non-brokered private placement offering of up to 10,000,000 units at $0.20 per unit.

MJ Biopharma is a private cannabis technology company based out of British Columbia that is currently focused on manufacturing breath strips, time release capsules, extract oils, food products such as infused juices, teas, coffee and extract drinks, as well as the development of pharmaceutical grade delivery systems. The company is also focused on licensing and partnering on the development of technologies and products for the medical and recreational cannabis market in Canada and abroad.

Vinergy’s market sentiment has improved significantly following the acquisition and investors were able to acquire stock at a more than 50% discount to the current price through the private placement. The offering generated incredible interest and is very oversubscribed. Investors should keep an eye on Vinergy as we expect to see the company build off of this momentum.

An Agreement Based on Success

One of the reasons why we were favorable on the aquisiton of MJ BioPharma was due to the milestone-based compensation strucutre. Vinergy issued 5 million shares to MJ BioPharma shareholders and can issue up 3.75 million more shares based on the completion of certain milestones.

  • The company will issue an additional 2.75 million shares upon the commercialization of MJ BioPharma’s strip technology.
  • One million shares will be issued when each of two alternative selected extractions/products are ready for commercialization.

Banking on Biotech

Although we continue to expect the biotech sector to benefit the legal cannabis movement, we are watching how these companies are impacted by a new White House administration.

The biotech sub-sector of the cannabis industry is comprised of some of the most mature cannabis businesses. We continue to view these companies as some of the most attractive cannabis investments and want to discuss our view of these companies at their current levels.

GW Pharmaceuticals (GWPH) has rallied off its recent lows and we remain bullish on the company due to its deep pipeline of pharmaceutical products that are in advanced stages of FDA testing. The company has a number of catalysts in the back half of 2017 and we see significant upside to current levels.

Zynerba Pharmaceuticals (ZYNE) continues to remain one of our top picks in the cannabis sector as we see significant upside to current levels. The average Wall Street price target on ZYNE is north of $30 and we view the company as an acquisition candidate for any biotech company interested in the cannabis industry.

Insys Therapeutics (INSY) has also rallied off its recent lows and the shares fell more than 60% during 2016. We believe that all of the legal concerns are priced into INSY and see significant upside to current levels. Like Zynerba, we view Insys as an acquisition candidate and view the company as a long-term investment opportunity.

 

Join Technical420 and Capitalize on the Rapidly Growing Cannabis Industry…

 

Important Investor Disclosures 

Disclosure.  Compensated Affiliate.  This report was authored by and is property of StoneBridge Partners LLC.  All information and data relied upon in drafting this report is publicly available.  The author believes and considers its sources to be reliable, but does not guarantee the accuracy or completeness of any information contained in this report.  Any and all information, data, analyses and opinions are provided for informational purposes only and is not intended, in any manner, as investment advice.  Any projections or other information generated by StoneBridge Partners LLC regarding the likelihood of various investment outcomes are hypothetical in nature, do not reflect actual investment results, and are not guarantees of future results.  None of the material contained in this report is intended as a solution or offer to sell or purchase a specific stock or any other investment.  This report is not directed to, or intended for distribution or use by, any person or entity that is a citizen, resident or located in any municipality, state, country or other jurisdiction where the distribution, publication, availability, or use of this report is contrary to any governing law or regulation.  The securities discussed in this report may not be eligible for purchase and/or sale in certain jurisdictions or by particular individuals.  It is important that you check any and all governing laws and/or regulations that may be applicable in your jurisdiction.  Investing in securities of issuers organized outside of the United States, including ADRs, entail certain risks.  The securities of non-United States issuers may not be registered with, nor be subject to the reporting requirements of the United States Securities and Exchange Commission.  Please contact a Financial Advisor for professional advice regarding any and all securities investments.  This report is intended for informational purposes only.  StoneBridge Partners LLC’s officers, directors, employees, affiliates, or subsidiaries may have positions in securities covered by StoneBridge Partners LLC.  StoneBridge Partners LLC receives compensation from the company and/or has a position in the securities mentioned in this report

 

Authored by: Micheal Berger

0 3749

Canadian cannabis leader Canopy Growth announced that it closed an approximately $7 million stock offering for the recently formed Canopy Health Innovations.

Canopy Health is partly owned by Canopy Growth and private investors. The company operates as a pure research incubator whose mission is to increase the understanding of cannabis based therapies through research, to drive product innovation and to develop an intellectual property portfolio that can be built into commercial opportunities for Canopy Growth and its subsidiaries.

Plans to Commence Clinical Research Studies

Canopy Health will use the proceeds to establish general operations and begin clinical research into the effectiveness of clinically ready whole plant cannabis drug formulations and dose delivery systems on specific indications. The company will conduct clinical research in partnership with licensed third parties, including Canopy Growth.

Canopy Growth CEO Bruce Linton said his intention with Canopy Health is to build an extension of the business that is dedicated to product specialization. By defining how to apply specific cannabis profiles and delivery systems to certain conditions, Canopy will be able to drive physician acceptance and grow the market at the same time.

Pursuant to agreements between the companies, Canopy Growth will act as a primary supplier of cannabis products for clinical research. It will also act as a research partner through its Tweed Inc. subsidiary which recently acquired a Dealer’s License from Health Canada. This license allows Tweed to possess cannabis and cannabis by-products for the purposes of analytical testing. It also allows the company to use these products for the commercialization of intellectual property by Canopy Health.

Canopy Hires a Founding President and Director

Canopy Growth (CGC.TO) (TWMJF) also announced that Marc Wayne will join Canopy Health as its founding President and Director. Wayne is thought of as a pioneer in the Canadian medical cannabis field having co-founded Bedrocan Canada and serving as its founding Chair.

Wayne played a key role in helping develop the Canadian Consortium for the Investigation of Cannabinoids and turning it into a global innovator in education and research on the medical uses of cannabis. Effective upon the closing of the offering, Wayne resigned from his position as Managing Director of Canopy Growth Corp and as President of Bedrocan Canada Inc.

Completes $60 Million Capital Raise

This morning, Canopy Growth announced that it closed its previously announced $60+ million capital raise at $10.60 a share. The offering was underwritten by a syndicate of underwriters led by GMP Securities L.P. and Dundee Capital Partners, and including Cormark Securities, PI Financial, and Canaccord Genuity .

Canopy Growth intends to use the proceeds for potential real estate acquisitions and fit-up of growing operations at such locations. In the event such potential acquisitions are not completed, a majority of the funds will be used to expand capacity at its existing sites over the next 12 months. Additionally, the company expects to incur international development expenditures of approximately $2,000,000 primarily to further explore and develop international market opportunities where federally legal to do so.

The balance of the net proceeds will be used for general working capital purposes, such as potential acquisitions for both capacity and brand augmentation and related integration, and developing new product offerings. The company may reallocate these funds as market and regulatory indicators warrant in light of the anticipated legalization of a national recreational cannabis market and the ACMPR.

An Emerging Trend

Over the last quarter, we have noticed a trend in the emerging Canadian cannabis industry where licensed producers are significantly increasing their focus on the development of cannabis drug formulations and dose delivery systems for specific ailments and debilitating illnesses.

Earlier this month, Emblem Corp (EMC.V) (EMMBF) commenced trading on the TSX venture exchange after a very successful initial public offering. The company is comprised of three distinct divisions. One of the company’s divisions is Emblem Pharmaceuticals and it is focused on pioneering the next generation of Canadian medical cannabis by providing medication in standard pharmaceutical dosage formats.

Emblem Pharmaceuticals is a very attractive aspect of the business as it offers investors leverage to not only the legal cannabis market but also the cannabis pharmaceutical market.

In the second quarter of 2017, Emblem Pharmaceuticals President John Stewart will lead the launch of cannabinoid-based medications in customary pharmaceutical dosage forms such as liquids, gel caps, oral sprays, and inhalers.

Stewart has over 30 years experience developing and commercializing pharmaceutical products. He has launched 11 new products, including OxyContin, and was the worldwide President and CEO of Purdue Pharma, the largest privately held pharmaceutical company in the world.

Since inception, management has invested over $6 million in the company and executed flawlessly on the business plan to create a production facility that offers premium products. We are very excited about Emblem’s opportunity within the pharmaceutical market of the cannabis industry on account of its best-in-class leadership, its state-of-the-art production facility and its continued execution.

Important Investor Disclosures

Disclosure. Compensated Affiliate. This report was authored by and is property of StoneBridge Partners LLC. All information and data relied upon in drafting this report is publicly available. The author believes and considers its sources to be reliable, but does not guarantee the accuracy or completeness of any information contained in this report. Any and all information, data, analyses and opinions are provided for informational purposes only and is not intended, in any manner, as investment advice. Any projections or other information generated by StoneBridge Partners LLC regarding the likelihood of various investment outcomes are hypothetical in nature, do not reflect actual investment results, and are not guarantees of future results. None of the material contained in this report is intended as a solution or offer to sell or purchase a specific stock or any other investment. This report is not directed to, or intended for distribution or use by, any person or entity that is a citizen, resident or located in any municipality, state, country or other jurisdiction where the distribution, publication, availability, or use of this report is contrary to any governing law or regulation. The securities discussed in this report may not be eligible for purchase and/or sale in certain jurisdictions or by particular individuals. It is important that you check any and all governing laws and/or regulations that may be applicable in your jurisdiction. Investing in securities of issuers organized outside of the United States, including ADRs, entail certain risks. The securities of non-United States issuers may not be registered with, nor be subject to the reporting requirements of the United States Securities and Exchange Commission. Please contact a Financial Advisor for professional advice regarding any and all securities investments. This report is intended for informational purposes only. StoneBridge Partners LLC’s officers, directors, employees, affiliates, or subsidiaries may have positions in securities covered by StoneBridge Partners LLC. StoneBridge Partners LLC receives compensation from the company and/or has a position in the securities mentioned in this report

 

Authored By: Michael Berger

To read more from Michael Berger’s take on Biotech companies read this

    12 28118

    The Future of Cannabis Biotech

    With some of the most successful fund managers in the world believing a Trump Presidency will benefit the biotech industry more than any other sector and legalization of both recreational and medical cannabis quickly spreading across the country, we feel it’s absolutely necessary to have cannabis biotech in your portfolio right now. Todd Hagopian, the most successful biotech fund manager in the market today, has even said he thinks the entire biotechnology market is about to double.

    That is why we feel there couldn’t be a better time to introduce our readers to Vitality Biopharma (VBIO). This emerging cannabis biotech company is rapidly gaining investor interest while focusing on the treatment of inflammatory bowel disease, narcotic bowel syndrome, and multiple sclerosis. Furthermore, the Company’s proprietary glycosylation technology for producing cannabinoid prodrugs could, in fact, revolutionize the entire cannabis biotech industry and change how CBD treatments are administered to patients. Steering the ship at the forefront of this technology are two biotech experts who already built two highly successful NASDAQ biotech companies.

    But before we get into VBIO’s veteran management team, let’s take a look at a type of technology that could mold the future of cannabis biotech.

    Potential Game-Changing Technology

    Vitality Biopharma recently announced they had developed a new class of cannabinoid prodrugs, known as cannabosides. Prodrugs are often designed to improve bioavailability when a drug itself is poorly absorbed from the gastrointestinal tract, or to overcome other issues like harsh side effects. Early independent trial results show that VBIO’s technology could change how all current CBD treatments are administered.

    VBIO’s cannabosides are more stable and soluble than regular cannabinoids, meaning there is less risk of non-psychotropic cannabidiol (CBD) being converted to psychotropic THC or otherwise being degraded or diluted in the acidic stomach environment. Upon ingestion, these cannabosides can enable the selective delivery of THC and CBD to the gastrointestinal tract. Site-specific delivery could enable oral drug formulations of cannabinoids to provide therapeutic benefits without having THC enter the bloodstream. For example, a prodrug could target a specific tissue or organ, such as the brain or gut, giving the patient better results with far less side effects.

    In addition to providing targeted delivery, cannabosides could enable a better tasting formulation for improved patient compliance, better oral bioavailability that provides safer and more reliable dosing, and a delayed release mechanism that enables patients using these medications to have long-lasting, overnight relief.

    As of 2015, there were approximately 15 prodrugs classified as blockbusters, meaning they had annual sales exceeding $1billion.

    Vitality Bio creates the cannaboside prodrugs through enzymatic glycosylation, a process perfected in 2015. Management believes that glycosylation of cannabinoids can improve product bioavailability, eliminate unwanted side effects, and be useful in any medical treatment where oral CBD is administered at a high dose. Independent studies have already demonstrated reliable and improved targeting to specific tissue/organs upon oral delivery of GBD glycoside prodrugs vs. active CBD.

    The Company’s goal is to ultimately provide a compelling oral cannabinoid pharmaceutical that physicians will be eager to prescribe and patients will prefer.

    VBIO Compared to the Competition

    Many synthetic cannabinoids on the market today are poorly soluble. GW Pharma’s (GWPH) two leading products, Epidiolex® and Sativex® are solutions. Sativex is a mixture of CBD/THC solubilized with 50% v/v alcohol (ethanol) into an oral spray. Although the alcohol volume is small, it can still cause problems for alcoholics, pregnant women, and young children. Oral lesions may also form in users of alcohol-based cannabis sprays, coupled with reported stinging, bad taste, and dry mouth. Sativex also contains propylene glycol, which may cause further irritation and dry mouth. The product must be stored in the refrigerator and has a shelf life of only 42 days. An oral capsule cannaboside prodrug developed by VBIO may alleviate many of these problems.

    Other companies, such as Zynerba Pharmaceuticals (ZYNE), are developing cannabinoid transdermal patches. Transdermal delivery routes can in some cases lead to hives/skin irritation, and typically deliver relatively small drug dosages. Oral cannaboside capsules avoid this problem and could enable far more convenient delivery of cannabinoids in a form that is fast-acting and that works at a high dose for maximal effect.

    We believe prodrug development like VBIO’s cannabosides is the future of the medical cannabis industry.

    Now, let’s make one thing clear. We are not saying that GW Pharma or Zynerba have poor drug treatments. What we are saying is that we believe VBIO’s technology could make them far better.

    Creating prodrugs is already a commercially validated strategy used by big pharma companies to improve drug efficacy and reduce side effects in non-cannabis related drugs. And because the reference drug or original drug already has independent verification and/or approval of its safety and efficacy, the prodrug can be approved much quicker by simply demonstrating similar safety and efficacy as the original. At the same time, a prodrug can be far more marketable due to its ability to eliminate unwanted side effects or undesirable commercial aspects. A classic prodrug example is Aspirin (acetylsalicylic acid), a synthetic prodrug of salicylic acid.

    It comes down to this…

    Cannabis biotech is still a very young industry, infant you could even say. And just like how the pharmaceutical industry matured and advanced using prodrug formulations of existing drugs to achieve higher efficacy and less side effects, the cannabis biotech industry will follow the same path. Drugs like GWPH’s Sativex and Epidiolex may be some of the first drugs to hit the market but that doesn’t mean they are the best, or even the best version of themselves. It is often times the prodrug variation of an approved drug that surpasses the $1billion annual sales mark; like we saw with Aspirin, the prodrug of salicylic acid.

    VBIO Drug Pipeline

    Through its glycosylation technology, Vitality Bio has produced more than 25 novel cannabosides and has patent applications pending that include composition of matter claims for prodrugs of cannabinoids that have been studied extensively in clinical trials worldwide, including THC, CBD, and cannabidivarin (CBDV).

    VBIO’s IP portfolio includes 79 patent claims and almost 200 individual compounds,

    including novel glycoside prodrugs of the most abundant phytocannabinoids, THC and CBD, as well as a variety of other phytocannabinoids and endocannabinoids.

    The company aims to develop and receive approval for these proprietary molecules as pharmaceuticals by taking advantage of the more efficient FDA review and approval process that is available for prodrugs. This greatly reduces the need for large and expensive clinical trials. Because clinical studies have already been performed or are currently still in process for many large commercial indications such as epilepsy, neuropathic pain, multiple sclerosis, inflammatory bowel disease, schizophrenia, and Huntington’s disease, management aims to create improved prodrug formulations of these cannabinoids that ultimately deliver a superior product.

    Vitality Biopharma’s two main drugs are moving towards beginning Phase I/Phase II studies in 2017.

    • VB100 – Inflammatory Bowel Disease, Narcotic Bowel Syndrome
    • VB210 – Neuropathic Pain, Irritable Bowel Syndrome, Opiate-induced Bowel Dysfunction, Muscle Spasticity in Multiple Sclerosis

    “Independent clinical trials have shown VBIO’s prodrugs retain almost all of the benefits of cannabinoids and, furthermore, they can be approved by the FDA at a far lower cost and on an accelerated timeline.” – according to Insider Financial Magazine

    With the current state of the biotech and cannabis markets, we feel it is important for investors to familiarize themselves with VBIO right now. The value and growth opportunities with biotech investments are before they start announcing potentially positive data from Phase I/Phase II/Phase III clinical trials. That is because positive study data and trial results tend to significantly increase biotech company stock prices. It is not uncommon for a biotech company’s stock to go up 100% or even 300% in a single trading day after announcing such data.

    Strong Management from Successful NASDAQ Biotech Companies

    CEO – Robert Brooke

    Mr. Brooke is a biomedical engineer and experienced biotech entrepreneur. He was the founder of a drug development company that became Lion Biotechnologies (NASDAQ: LBIO) in 2013. He also co-founded Intervene Immune. Mr. Brooke also had a successful hedge fund stint as an analyst for Bristol Capital, responsible for more than 50 direct healthcare investments.

    Chairman & Co-Founder – Avtar Dhillon, MD

    Mr. Dhillon has extensive biotech experience. He is currently Chairman of three biotech companies: Inovio Pharmaceuticals (NASDAQ: INO), Oncosec Medical (NASDAQ: ONCS) and Arch Therapeutics (ARTH). He has also raised over $200 million in public markets to ensure that his companies have sufficient research funding that is critical to a biotech company’s success. Mr. Dhillon is also a former venture capitalist and family physician for more than 10 years.

    Director of Research and Development, Scientific Co-Founder – Brandon Zipp, PhD

    Dr. Zipp is a scientist with over 10 years of research experience with glucosyltransferase enzymes – the enzymes used in VBIO’s proprietary development process. He has a Ph.D Biochemistry and Molecular Biology from the University of California, Davis.

    We always say you invest in management. And what we mean by that is no matter how great a company’s product or technology is, you need a capable management team to properly bring it to market. A cure for cancer in a lab does a company and its shareholders no good if the management team cannot commercialize the drug and bring it to market. Companies will encounter several financial hurdles and operational speed bumps along the way. A good management team can overcome these obstacles while staying focused on their goal and progressing through their business plan, in turn, building shareholder value. This is why it is important to invest in companies with proven and successful management teams.

    Conclusion

    The medical marijuana and cannabis industry is booming. And the biotech industry is poised for a massive bull run with Donald Trump winning the election. Right now could be the perfect time to add cannabis biotech to your portfolio.

    What was hype and speculation only a few years ago is now an investable market with tremendous upside. At the center of the industry is biopharma R&D being pioneered by companies with proprietary technology and the intellectual property leading to exciting medical breakthroughs. Just as prodrug development advanced the non-cannabis pharmaceutical market, we expect similar technology to help mature an infant biotech cannabis industry.

    Vitality Bio is currently conducting preclinical studies in anticipation of filing IND applications in 2017 for glycosylated cannabinoid products called cannabosides. The most advanced candidate is VB100, a cannaboside prodrug under development for the acute management of inflammatory bowel disease. A second candidate, VB210, is under development for chronic conditions that affect both the GI and CNS. With a strong IP portfolio of 79 patent claims on over 200 compounds and a proven, successful management team, VBIO could be set up to benefit from an overall cannabis biotech rally and is already quickly gaining investor interest.

     

     

     

     

     

     

     

     

     

     


    Pursuant to an agreement between MAPH and a non affiliate third party, we were hired for a period of 30 days to publicly disseminate information about (VBIO) including on the Website and other media including Facebook and Twitter. We are being paid $100,000 (CASH) for or were paid “ZERO” shares of unrestricted or restricted common shares. We own zero shares of (VBIO), which we purchased in the open market. We plan to sell the “ZERO” shares of (VBIO) that we hold during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of (VBIO) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.

    0 837

    GW Pharmaceuticals to Present at the 28th Annual Piper Jaffray Healthcare Conference on 29 November

    GW Pharmaceuticals plc (GWPH) (GWP.L) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that Justin Gover, GW’s Chief Executive Officer, will present at the 28th Annual Piper Jaffray Healthcare Conference on Tuesday, 29 November 2016, at 10:30 a.m. ET at the Lotte New York Palace, New York City.

    A live audio webcast of the presentation will be available through GW’s corporate website in the investor relations section from the investor’s calendar of events page at www.gwpharm.com. A replay will be available soon after the live presentation.

    About GW Pharmaceuticals plc

    Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW is advancing an orphan drug program in the field of childhood epilepsy with a focus on Epidiolex® (cannabidiol), which is in Phase 3 clinical development for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, Tuberous Sclerosis Complex and Infantile Spasms. GW commercialized the world’s first plant-derived cannabinoid prescription drug, Sativex®, which is approved for the treatment of spasticity due to multiple sclerosis in 30 countries outside the United States. The Company has a deep pipeline of additional cannabinoid product candidates which includes compounds in Phase 1 and 2 trials for glioma, schizophrenia and epilepsy. For further information, please visit www.gwpharm.com.

    0 5452

    With the presidential election right around the corner and a record number of states voting on legal cannabis ballot initiatives, 2016 will be a banner year for the cannabis industry.

    We believe that the 2016 election will be a watershed moment for the cannabis industry as states like California and Florida vote to expand existing cannabis programs. California will vote on recreational cannabis and Florida will vote on medical cannabis. These two states could have a significant impact on the legal cannabis industry.

    Democratic presidential candidate Hilary Clinton is considerably ahead of Republican presidential candidate Donald Trump in the polls and has repeatedly said that she would like to re-categorize cannabis from a Schedule 1 to a Schedule 2 substance so that researchers can better investigate its uses and limitations.

    Top Five Pre-Election Cannabis Stocks

    Although the legal cannabis industry has gained a lot of ground in the last two years we are still in the first inning of a multi-decade growth cycle. From an investor standpoint, there are several ways to capitalize on this opportunity but the best and easiest avenue is through investing in publicly traded companies.

    Although many cannabis stocks have already had remarkable rallies, we think this is just the beginning and want to highlight five stocks that we expect to benefit from the election:

    Medicine Man Technologies (MDCL) provides cultivation consulting services focused on cannabis growing technologies and methodologies. Medicine Man has clients in Arizona, California, Florida, Maryland, Nevada, Oregon, Ohio, Oklahoma, Ohio, Pennsylvania, Texas, and Puerto Rico. We have been favorable on the company as it would directly benefit from a positive election result.

    American Cannabis Company (AMMJ) provides advisory and consulting services for cannabis businesses in the United States and Canada. American Cannabis generates revenue from the sales of products used in the cultivation, processing, and sale of cannabis. The company also generates revenue through its consulting clients across the country. American Cannabis is levered to the election via its consulting clients as well as its product business.

    MassRoots (MSRT) has been called the Instagram of the cannabis industry and its mobile app can be downloaded only in states where medical cannabis is legal. The election is a significant event for MassRoots because a successful outcome would enable the company to reach more users and businesses in states that pass cannabis ballot initiatives.

    GW Pharmaceuticals (GWPH) is the bellwether of the cannabis industry and tends to benefit from any positive development in the cannabis industry. We continue to view GW Pharmaceutical as the best long-term cannabis investment due to its deep pipeline of products, its successful FDA testing results, its Wall Street coverage, and its valuation as its shares are trading well below the average Wall Street price target.

    Kush Bottles (KSHB) is focused on providing exit bag products that are in compliance with regulations. We see a lot of opportunity for growth as new state markets open and existing markets develop. We are favorable on Kush Bottles due to the product it provides, its geographic diversity and its continued execution.

    Authored By: Michael Berger

    Subscribe Now & Begin Receiving Marijuana Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

    We are your #1 source for all things Marijuana Stocks, Subscribe Below!

    Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on marijuana stocks related, articles, news and trade alerts. Further questions please contact privacy@marijuanastocks.com
    Ad Placements